Developer docs
API playgroundTry for free, no card

Search company profiles

Cellid

Full company profile

uuid0007lsk

Namestring
Cellid
Legal namestring
주식회사 셀리드
Websiteurl
cellid.co.kr
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Cellid Co., Ltd. (주식회사 셀리드) is a Seoul-headquartered, KOSDAQ-listed (ticker 299660) clinical-stage biopharmaceutical company founded in 2006 from a laboratory at Seoul National University's College of Pharmacy. Its core technology is the CeliVax platform, which uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells (APCs) — described as a world-first approach — combined with tumor antigen genes and an alpha-galactosyl ceramide immunological adjuvant to simultaneously activate CD8+ T cells, CD4+ T cells, NK cells, NKT cells, and antibody-producing B cells. The platform can be reconfigured by swapping tumor antigens, enabling a pipeline of six BVAC candidates: BVAC-C (HPV-positive cervical cancer, Phase 2 with combination data at ASCO/SGO), BVAC-E6E7 (head and neck cancer, Phase 1/2a initiated December 2025), BVAC-B (HER2+ gastric cancer, Phase 1 complete), BVAC-P (prostate cancer/glioblastoma), BVAC-M (melanoma), and BVAC-Neo (personalized neoantigen therapy licensed to LG Chemistry in May 2021 for up to KRW 1.835 trillion in upfront, milestones, and royalties).

Cellid also operates a proprietary non-replicating adenovirus vector platform, which underpins the AdCLD-CoV19 series of COVID-19 vaccines (AdCLD-CoV19-1, OMI, LP.8.1, BA.3.2). The AdCLD-CoV19-1 OMI Phase 3 trial reported in June 2026 demonstrated a favorable safety profile (26.66% adverse events vs. 66.52% for the Pfizer comparator) but failed to establish immunogenicity non-inferiority versus Pfizer, blocking near-term NDA. Revenue today is dominated by the Gomeon premium baking ingredients e-commerce brand (KRW 85 billion+ in 2025, ~2x growth), with biopharma revenue still primarily milestone-based (e.g., LG Chemistry licensing, government R&D grants from KDDF and Ministry of Science & ICT). The company also runs a CDMO business at its Seongnam GMP facilities (Vector GMP plant 618m², Cell & Gene Therapy GMP plant 925m²) serving domestic and international biotech clients, and has partnerships with IVI, CEPI/COVAX, Vinnex, Samsung Medical Center, and others.

Short descriptiontext

Cellid is a KOSDAQ-listed Seoul biopharmaceutical company developing CeliVax-based cancer immunotherapy vaccines (six BVAC candidates) and AdCLD-CoV19 COVID-19 vaccines, using proprietary non-replicating adenovirus vectors, with a CDMO business and a Gomeon e-commerce revenue stream.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy vaccines, cell gene therapy CDMO, adenovirus vector vaccines, GMP biopharmaceutical manufacturing, infectious disease prevention
Industry4 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy Vaccines
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Biopharmaceutical Licensing & Royalties
TypeLicensing Royalties
Description

License-out of CeliVax platform and BVAC pipeline to large pharmaceutical companies for global development and commercialization. Revenue from upfront payments, milestone payments tied to development and regulatory achievements, and ongoing royalties on net sales. Example: LG Chemistry BVAC-Neo license deal valued at up to KRW 1,835 billion including upfront and milestones.

cellid.co.kr
2CDMO / CMO Services
TypeManaged Services
Description

Cellid operates GMP-certified manufacturing facilities offering contract development and manufacturing services for cell & gene therapies, viral vectors, and vaccines to domestic and international biotech/pharma companies.

cellid.co.kr
3COVID-19 Vaccine Product Sales
TypeOne Time License
Description

Revenue from sales of COVID-19 preventive vaccines (AdCLD-CoV19 series) to government agencies, hospitals, and international organizations pending regulatory approval. Target markets include national immunization programs and COVAX supply.

cellid.co.kr
4E-commerce (Gomeon brand)
TypeTransaction Fee
Description

Revenue from premium baking ingredient e-commerce brand 'Gomeon' sold through Naver Smart Store, Coupang and other major online platforms. Reported KRW 85 billion+ revenue in 2025 (2x prior year), providing financial stability separate from biopharma operations.

cellid.co.kr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 9 records shown
1CeliVax
Description

Original technology platform for anti-cancer immunotherapeutic vaccines using B cells, NK cells and monocytes

cellid.co.kr
+8 more records
Core offering1 text field

Cellid develops anti-cancer immunotherapy vaccines built on its proprietary CeliVax platform, which uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells combined with tumor antigen genes and alpha-galactosyl ceramide adjuvant to activate multiple anti-tumor immune pathways. The portfolio includes the BVAC pipeline (BVAC-C, BVAC-E6E7, BVAC-B, BVAC-P, BVAC-M, BVAC-Neo) targeting cervical, head and neck, gastric, prostate, melanoma, and personalized cancers, plus the AdCLD-CoV19 series of COVID-19 preventive vaccines. Cellid also operates GMP-certified manufacturing facilities offering CDMO services for cell therapy, gene therapy, and viral vector production to domestic and international biotech and pharmaceutical clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • BVAC-C Phase 2a: ORR 27%, DCR 40% in 15 evaluable patients with recurrent/metastatic cervical cancer; one complete remission maintained >2 years without relapse; PFS 4 months (2-27+ months) and DoR 9-27+ months
+3 more records
Product overview1 text field

Cellid is a Korean biotech company developing a portfolio of cancer immunotherapy vaccines and infectious disease preventive vaccines based on its proprietary CeliVax platform technology. The CeliVax platform uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells to activate comprehensive immune responses against cancer cells. The product portfolio includes six BVAC pipeline products (BVAC-C for cervical cancer, BVAC-E6E7 for head and neck cancer, BVAC-B for gastric cancer, BVAC-P for prostate cancer, BVAC-M for melanoma, and BVAC-Neo for personalized therapy) and multiple COVID-19 vaccine candidates (AdCLD-CoV19-1, AdCLD-CoV19-1 OMI, AdCLD-CoV19-1 LP.8.1). The company also operates CDMO services through its GMP-certified manufacturing facilities for cell therapy, gene therapy, and vaccine production.

Product and service11 records
1CeliVax Platform
CategoryBiopharmaceutical Platform Technology
Description

Cellid's proprietary anti-cancer immunotherapeutic vaccine technology that uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells combined with tumor antigen genes and an alpha-galactosyl ceramide immunological adjuvant, enabling simultaneous activation of CD8+ T cells, CD4+ T cells, NK cells, NKT cells, and antibody-producing B cells. Applicable to any cancer with identified tumor antigens.

2BVAC-C
CategoryOncology Vaccine
Description

Anti-cancer immunotherapy vaccine targeting HPV type 16/18 positive cervical cancer using HPV E6/E7 recombinant gene as antigen on the CeliVax platform. In Phase 2 clinical development, with investigator-initiated combination therapy trials with Durvalumab ongoing.

3BVAC-E6E7
CategoryOncology Vaccine
Description

Anti-cancer immunotherapy vaccine for head and neck cancer using HPV type 16/18 E6/E7 recombinant gene antigen on the CeliVax platform. Currently in Phase 1/2a clinical trial.

4BVAC-B
CategoryOncology Vaccine
Description

Anti-cancer immunotherapy vaccine for HER2/neu positive gastric cancer using HER2/neu recombinant gene on the CeliVax platform. Completed Phase 1 clinical trial and preparing for Phase 2.

5BVAC-P
CategoryOncology Vaccine
Description

Anti-cancer immunotherapy vaccine using PAP/PSMA fusion cancer antigen on the CeliVax platform for prostate cancer, renal cell cancer, and glioblastoma.

6BVAC-M
CategoryOncology Vaccine
Description

Anti-cancer immunotherapy vaccine using GP100/MAGE-A3 fusion antigen on the CeliVax platform for melanoma.

7BVAC-Neo
CategoryPersonalized Oncology Vaccine
Description

Fully personalized cancer immunotherapy vaccine using neo-epitopes identified in each individual patient as antigens on the CeliVax platform. Licensed to LG Chemistry for global development and commercialization.

8AdCLD-CoV19-1
CategoryInfectious Disease Vaccine
Description

COVID-19 preventive vaccine using SARS-CoV-2 spike protein recombinant gene delivered via Cellid's proprietary non-replicating adenovirus vector platform. Completed Phase 2b clinical trial.

9AdCLD-CoV19-1 OMI
CategoryInfectious Disease Vaccine
Description

COVID-19 Omicron variant preventive vaccine using SARS-CoV-2 B.1.1.529 spike protein recombinant gene delivered via Cellid's non-replicating adenovirus vector platform. Phase 3 clinical trial completed with safety endpoint met.

10CDMO Services
CategoryBiopharmaceutical CDMO Services
Description

Contract development and manufacturing organization services offering cell therapy, gene therapy, viral vector (adenovirus, lentivirus, AAV, retrovirus), vaccine, and CAR-T development and GMP manufacturing from early development through commercial supply. Serves domestic and international biotech and pharmaceutical companies.

11GMP Manufacturing Center
CategoryGMP Manufacturing Facility
Description

Global-standard GMP-certified manufacturing facilities including Vector GMP plant, Cell & Gene Therapy GMP plant, BSL2 viral vector production facility, aseptic process room, vial filling lines (1500 vials/hour), LN2 storage, and integrated QC laboratory. Operates under MFDS, ATMP, and human-derived material manufacturing licenses.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Korea National Institute of Health (국립보건연구원)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-03-21
Description

Clinical trial sample analysis agreement with National Institute of Infectious Diseases under KDCA. NIн provides BSL-3 facilities, national standard reference materials, and standardized testing methods for neutralizing antibody efficacy evaluation of AdCLD-CoV19-1. Analysis enhances international credibility for MFDS approval and WHO PQ certification.

cellid.co.kr
2CEPI / COVAX
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-10-04
Description

COVAX Marketplace User Agreement signed October 2021. Cellid participates in the CEPI-coordinated international vaccine procurement project for fair and equitable global distribution of COVID-19 vaccines. Cellid requests and offers critical manufacturing supplies and aims to supply AdCLD-CoV19-1 through COVAX pending positive clinical results and WHO EUL approval.

cellid.co.kr
3Vinnex (바이넥스)
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-08-30
Description

CMO (contract manufacturing organization) agreement for large-scale commercial production of COVID-19 vaccine AdCLD-CoV19-1. Vinnex leverages its 12,000L bioreactor capacity to provide additional manufacturing capability for vaccine supply. Partnership supports domestic and WHO emergency approval production needs.

cellid.co.kr
4International Vaccine Institute (IVI, 국제백신연구소)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-29
Description

Clinical development cooperation agreement for global Phase 2b/3 trials and regulatory approval of AdCLD-CoV19-1 COVID-19 vaccine. IVI provides international clinical trial expertise, regulatory strategy support, and connections to WHO and global health agencies. Trial results intended for submission to Korean MFDS, WHO, and multiple international regulatory authorities.

cellid.co.kr
5LG Chemistry (LG화학)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-05-26
Description

Global license-out agreement for CeliVax-based personalized neoantigen cancer immunotherapy vaccine (BVAC-Neo). Cellid receives KRW 10 billion upfront payment, up to KRW 1,825 billion in development and regulatory milestones, plus royalties on net sales. LG Chemistry gains exclusive worldwide rights for development and commercialization of personalized cancer vaccines using Cellid's CeliVax platform technology combined with LG's own cell therapy platform.

cellid.co.kr
6International Vaccine Institute (IVI, 국제백신연구소)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-04
Description

Research service contract for safety and immunogenicity analysis of COVID-19 vaccine AdCLD-CoV19 clinical trial specimens. IVI analyzes clinical samples from Phase 1/2a trials to evaluate safety and immunogenicity profiles.

cellid.co.kr
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-12-18
Description

Clinical trial service agreement for Phase 1/2a of COVID-19 vaccine AdCLD-CoV19 at Guro Hospital, led by Professor Hee-Jin Jeong. Hospital serves as primary clinical trial site for early-stage COVID-19 vaccine development. Additional sites: Korea University Ansan Hospital, Hallym University Kangnam Sacred Heart Hospital, Catholic University Seoul St. Mary's Hospital, and Catholic University St. Vincent's Hospital.

8Animal Cell Technology Center (동물세포실증지원센터)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-07-13
Description

COVID-19 vaccine production cooperation agreement. Center provides GMP manufacturing facility and expertise for clinical trial vaccine production. Located in Andong Bioindustry Complex with BSL-level facilities and 16,120m² GMP manufacturing building. Partnership is part of a three-site production network (Seongnam GMP + Jeonnam JBRC + Andong Animal Cell Center).

cellid.co.kr
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Investigator-initiated clinical trial of BVAC-C in combination with Durvalumab for recurrent cervical cancer, led by Professor Byung-Kee Kim. Trial approved August 2020 (25 patients). Phase 2 results presented at SGO 2025 and ASCO 2024. Samsung Medical Center serves as lead site for BVAC-C + checkpoint inhibitor combination studies.

Strategic tierMinorTypeOthers
Description

CEO Kang Chang Yuil serves as Non-Executive Director at Handok Co., Ltd., a listed Korean pharmaceutical company, providing potential strategic connection to pharmaceutical distribution and commercialization networks.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

mRNA-based cancer vaccine pipeline (BNT122/iNeST, BNT111, etc.) and infectious disease vaccines. Comparable to Cellid as a leading therapeutic cancer vaccine developer with multiple oncology programs targeting similar indications (HPV-driven cancers, melanoma, personalized neoantigens).

TypeBroad incumbent
Description

Recombinant nanoparticle vaccine developer for infectious diseases (COVID-19, influenza, RSV) with Matrix-M adjuvant platform. Comparable to Cellid on the infectious disease vaccine side (AdCLD-CoV19 series) where both pursued COVID-19 vaccines and faced mRNA-driven competitive pressure.

TypeRegional player
Description

Korean biopharma leader with biosimilars, novel biologics, and CDMO services through Celltrion Pharm. Comparable to Cellid as a Korean biopharma with significant GMP manufacturing scale and CDMO operations, illustrating the scale gap and providing a benchmark for Korean biopharma CDMO economics.

TypeDirect peer
Description

mRNA-based cancer vaccine developer (CV8102, CV9202, personalized neoantigen vaccines) and infectious disease vaccines. Comparable to Cellid as a smaller-cap cancer/infectious disease vaccine biotech with platform-anchored multiple indication expansion strategy.

TypeDirect peer
Description

Clinical-stage biotech developing personalized neoantigen cancer vaccines (similar to Cellid's BVAC-Neo). Both companies pursue individualized cancer immunotherapy using patient-specific tumor antigens, making Gritstone the most directly comparable peer on the personalized vaccine side of CeliVax.

TypeDirect peer
Description

Vaccine biotech developing prophylactic and therapeutic vaccines including enveloped virus-like particle (eVLP) platforms for infectious disease and immunotherapeutic candidates. Comparable to Cellid as a small-cap multi-platform vaccine company pursuing both infectious disease and oncology indications.

TypeBroad incumbent
Description

mRNA platform with extensive oncology vaccine pipeline (mRNA-4157/V940 individualized neoantigen therapy, mRNA-5671 KRAS, Merck partnership) plus infectious disease vaccines. Highly comparable therapeutic cancer vaccine approach to CeliVax and BVAC-Neo via individual neoantigen targeting.

TypeDirect peer
Description

Vaccine-focused biotech with both infectious disease (smallpox/mpox, COVID-19, RSV) and oncology immunotherapy vaccine programs. Comparable to Cellid for its dual focus on prophylactic vaccines plus therapeutic cancer vaccines (CV301, BN-CV301) and global commercial reach.

TypeEmerging player
Description

Asia-Pacific cell therapy company developing CAR-T therapies (Carteyva/relmacabtagene autoleucel) with integrated GMP manufacturing. Comparable to Cellid on the cell/gene therapy manufacturing side given Cellid's GMP facility and CDMO ambitions for cell therapy and viral vector production.

TypeRegional player
Description

Korean KOSDAQ-listed biotech developing immunotherapies and DNA vaccines, including therapeutic cancer vaccine candidates (GX-188E for HPV-driven cervical cancer). Comparable to Cellid as a fellow Korean biotech operating in therapeutic cancer vaccines and HPV-driven indications, though with a DNA vaccine rather than APC approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellid

Cancer Immunotherapy Vaccinescellid.co.kr

Cellid is a KOSDAQ-listed Seoul biopharmaceutical company developing CeliVax-based cancer immunotherapy vaccines (six BVAC candidates) and AdCLD-CoV19 COVID-19 vaccines, using proprietary non-replicating adenovirus vectors, with a CDMO business and a Gomeon e-commerce revenue stream.

What Cellid does

Cellid Co., Ltd. (주식회사 셀리드) is a Seoul-headquartered, KOSDAQ-listed (ticker 299660) clinical-stage biopharmaceutical company founded in 2006 from a laboratory at Seoul National University's College of Pharmacy. Its core technology is the CeliVax platform, which uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells (APCs) — described as a world-first approach — combined with tumor antigen genes and an alpha-galactosyl ceramide immunological adjuvant to simultaneously activate CD8+ T cells, CD4+ T cells, NK cells, NKT cells, and antibody-producing B cells. The platform can be reconfigured by swapping tumor antigens, enabling a pipeline of six BVAC candidates: BVAC-C (HPV-positive cervical cancer, Phase 2 with combination data at ASCO/SGO), BVAC-E6E7 (head and neck cancer, Phase 1/2a initiated December 2025), BVAC-B (HER2+ gastric cancer, Phase 1 complete), BVAC-P (prostate cancer/glioblastoma), BVAC-M (melanoma), and BVAC-Neo (personalized neoantigen therapy licensed to LG Chemistry in May 2021 for up to KRW 1.835 trillion in upfront, milestones, and royalties).

Cellid also operates a proprietary non-replicating adenovirus vector platform, which underpins the AdCLD-CoV19 series of COVID-19 vaccines (AdCLD-CoV19-1, OMI, LP.8.1, BA.3.2). The AdCLD-CoV19-1 OMI Phase 3 trial reported in June 2026 demonstrated a favorable safety profile (26.66% adverse events vs. 66.52% for the Pfizer comparator) but failed to establish immunogenicity non-inferiority versus Pfizer, blocking near-term NDA. Revenue today is dominated by the Gomeon premium baking ingredients e-commerce brand (KRW 85 billion+ in 2025, ~2x growth), with biopharma revenue still primarily milestone-based (e.g., LG Chemistry licensing, government R&D grants from KDDF and Ministry of Science & ICT). The company also runs a CDMO business at its Seongnam GMP facilities (Vector GMP plant 618m², Cell & Gene Therapy GMP plant 925m²) serving domestic and international biotech clients, and has partnerships with IVI, CEPI/COVAX, Vinnex, Samsung Medical Center, and others.

Cellid firmographics

Firmographics
Name
Cellid
Legal name
주식회사 셀리드
Website
https://cellid.co.kr
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Cellid is a KOSDAQ-listed Seoul biopharmaceutical company developing CeliVax-based cancer immunotherapy vaccines (six BVAC candidates) and AdCLD-CoV19 COVID-19 vaccines, using proprietary non-replicating adenovirus vectors, with a CDMO business and a Gomeon e-commerce revenue stream.
Ownership category
akta.pro rank

Cellid industry classification

Industry
Product category
Cancer Immunotherapy Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Cancer immunotherapy vaccines
  • Cell gene therapy CDMO
  • Adenovirus vector vaccines
  • GMP biopharmaceutical manufacturing
  • Infectious disease prevention

Where Cellid is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Cellid business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Biopharmaceutical Licensing & Royalties: License-out of CeliVax platform and BVAC pipeline to large pharmaceutical companies for global development and commercialization. Revenue from upfront payments, milestone payments tied to development and regulatory achievements, and ongoing royalties on net sales. Example: LG Chemistry BVAC-Neo license deal valued at up to KRW 1,835 billion including upfront and milestones.
  2. CDMO / CMO Services: Cellid operates GMP-certified manufacturing facilities offering contract development and manufacturing services for cell & gene therapies, viral vectors, and vaccines to domestic and international biotech/pharma companies.
  3. COVID-19 Vaccine Product Sales: Revenue from sales of COVID-19 preventive vaccines (AdCLD-CoV19 series) to government agencies, hospitals, and international organizations pending regulatory approval. Target markets include national immunization programs and COVAX supply.
  4. E-commerce (Gomeon brand): Revenue from premium baking ingredient e-commerce brand 'Gomeon' sold through Naver Smart Store, Coupang and other major online platforms. Reported KRW 85 billion+ revenue in 2025 (2x prior year), providing financial stability separate from biopharma operations.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Cellid product offering

Product offering

Core offering

Cellid develops anti-cancer immunotherapy vaccines built on its proprietary CeliVax platform, which uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells combined with tumor antigen genes and alpha-galactosyl ceramide adjuvant to activate multiple anti-tumor immune pathways. The portfolio includes the BVAC pipeline (BVAC-C, BVAC-E6E7, BVAC-B, BVAC-P, BVAC-M, BVAC-Neo) targeting cervical, head and neck, gastric, prostate, melanoma, and personalized cancers, plus the AdCLD-CoV19 series of COVID-19 preventive vaccines. Cellid also operates GMP-certified manufacturing facilities offering CDMO services for cell therapy, gene therapy, and viral vector production to domestic and international biotech and pharmaceutical clients.

Product overview

Cellid is a Korean biotech company developing a portfolio of cancer immunotherapy vaccines and infectious disease preventive vaccines based on its proprietary CeliVax platform technology. The CeliVax platform uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells to activate comprehensive immune responses against cancer cells. The product portfolio includes six BVAC pipeline products (BVAC-C for cervical cancer, BVAC-E6E7 for head and neck cancer, BVAC-B for gastric cancer, BVAC-P for prostate cancer, BVAC-M for melanoma, and BVAC-Neo for personalized therapy) and multiple COVID-19 vaccine candidates (AdCLD-CoV19-1, AdCLD-CoV19-1 OMI, AdCLD-CoV19-1 LP.8.1). The company also operates CDMO services through its GMP-certified manufacturing facilities for cell therapy, gene therapy, and vaccine production.

Differentiator

Problem solved

Functional benefit

Brands

  • CeliVax: Original technology platform for anti-cancer immunotherapeutic vaccines using B cells, NK cells and monocytes
  • BVAC-C
  • BVAC-E6E7
  • BVAC-B
  • BVAC-P
  • BVAC-M
  • BVAC-Neo
  • AdCLD-CoV19-1 OMI
  • 고메온

Products and services

  • CeliVax Platform Cellid's proprietary anti-cancer immunotherapeutic vaccine technology that uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells combined with tumor antigen genes and an alpha-galactosyl ceramide immunological adjuvant, enabling simultaneous activation of CD8+ T cells, CD4+ T cells, NK cells, NKT cells, and antibody-producing B cells. Applicable to any cancer with identified tumor antigens.
  • BVAC-C Anti-cancer immunotherapy vaccine targeting HPV type 16/18 positive cervical cancer using HPV E6/E7 recombinant gene as antigen on the CeliVax platform. In Phase 2 clinical development, with investigator-initiated combination therapy trials with Durvalumab ongoing.
  • BVAC-E6E7 Anti-cancer immunotherapy vaccine for head and neck cancer using HPV type 16/18 E6/E7 recombinant gene antigen on the CeliVax platform. Currently in Phase 1/2a clinical trial.
  • BVAC-B Anti-cancer immunotherapy vaccine for HER2/neu positive gastric cancer using HER2/neu recombinant gene on the CeliVax platform. Completed Phase 1 clinical trial and preparing for Phase 2.
  • BVAC-P Anti-cancer immunotherapy vaccine using PAP/PSMA fusion cancer antigen on the CeliVax platform for prostate cancer, renal cell cancer, and glioblastoma.
  • BVAC-M Anti-cancer immunotherapy vaccine using GP100/MAGE-A3 fusion antigen on the CeliVax platform for melanoma.
  • BVAC-Neo Fully personalized cancer immunotherapy vaccine using neo-epitopes identified in each individual patient as antigens on the CeliVax platform. Licensed to LG Chemistry for global development and commercialization.
  • AdCLD-CoV19-1 COVID-19 preventive vaccine using SARS-CoV-2 spike protein recombinant gene delivered via Cellid's proprietary non-replicating adenovirus vector platform. Completed Phase 2b clinical trial.
  • AdCLD-CoV19-1 OMI COVID-19 Omicron variant preventive vaccine using SARS-CoV-2 B.1.1.529 spike protein recombinant gene delivered via Cellid's non-replicating adenovirus vector platform. Phase 3 clinical trial completed with safety endpoint met.
  • CDMO Services Contract development and manufacturing organization services offering cell therapy, gene therapy, viral vector (adenovirus, lentivirus, AAV, retrovirus), vaccine, and CAR-T development and GMP manufacturing from early development through commercial supply. Serves domestic and international biotech and pharmaceutical companies.
  • GMP Manufacturing Center Global-standard GMP-certified manufacturing facilities including Vector GMP plant, Cell & Gene Therapy GMP plant, BSL2 viral vector production facility, aseptic process room, vial filling lines (1500 vials/hour), LN2 storage, and integrated QC laboratory. Operates under MFDS, ATMP, and human-derived material manufacturing licenses.

Quantifiable outcome

  • BVAC-C Phase 2a: ORR 27%, DCR 40% in 15 evaluable patients with recurrent/metastatic cervical cancer; one complete remission maintained >2 years without relapse; PFS 4 months (2-27+ months) and DoR 9-27+ months
  • +3 more outcomes

Companies that use Cellid

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Cellid technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Cellid partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered major, core and minor.

  • Korea National Institute of Health (국립보건연구원)majorStrategic or Co-development Partner · 21 March 2022Clinical trial sample analysis agreement with National Institute of Infectious Diseases under KDCA. NIн provides BSL-3 facilities, national standard reference materials, and standardized testing methods for neutralizing antibody efficacy evaluation of AdCLD-CoV19-1. Analysis enhances international credibility for MFDS approval and WHO PQ certification.
  • CEPI / COVAXmajorStrategic or Co-development Partner · 4 October 2021COVAX Marketplace User Agreement signed October 2021. Cellid participates in the CEPI-coordinated international vaccine procurement project for fair and equitable global distribution of COVID-19 vaccines. Cellid requests and offers critical manufacturing supplies and aims to supply AdCLD-CoV19-1 through COVAX pending positive clinical results and WHO EUL approval.
  • Vinnex (바이넥스)majorChannel Partner/ Reseller/ Distributor · 30 August 2021CMO (contract manufacturing organization) agreement for large-scale commercial production of COVID-19 vaccine AdCLD-CoV19-1. Vinnex leverages its 12,000L bioreactor capacity to provide additional manufacturing capability for vaccine supply. Partnership supports domestic and WHO emergency approval production needs.
  • International Vaccine Institute (IVI, 국제백신연구소)coreStrategic or Co-development Partner · 29 June 2021Clinical development cooperation agreement for global Phase 2b/3 trials and regulatory approval of AdCLD-CoV19-1 COVID-19 vaccine. IVI provides international clinical trial expertise, regulatory strategy support, and connections to WHO and global health agencies. Trial results intended for submission to Korean MFDS, WHO, and multiple international regulatory authorities.
  • LG Chemistry (LG화학)coreOEM/ Whitelabel/ Licensing Partner · 26 May 2021Global license-out agreement for CeliVax-based personalized neoantigen cancer immunotherapy vaccine (BVAC-Neo). Cellid receives KRW 10 billion upfront payment, up to KRW 1,825 billion in development and regulatory milestones, plus royalties on net sales. LG Chemistry gains exclusive worldwide rights for development and commercialization of personalized cancer vaccines using Cellid's CeliVax platform technology combined with LG's own cell therapy platform.
  • International Vaccine Institute (IVI, 국제백신연구소)coreStrategic or Co-development Partner · 4 January 2021Research service contract for safety and immunogenicity analysis of COVID-19 vaccine AdCLD-CoV19 clinical trial specimens. IVI analyzes clinical samples from Phase 1/2a trials to evaluate safety and immunogenicity profiles.
  • Korea University Guro Hospital (고려대학교 구로병원)majorStrategic or Co-development Partner · 18 December 2020Clinical trial service agreement for Phase 1/2a of COVID-19 vaccine AdCLD-CoV19 at Guro Hospital, led by Professor Hee-Jin Jeong. Hospital serves as primary clinical trial site for early-stage COVID-19 vaccine development. Additional sites: Korea University Ansan Hospital, Hallym University Kangnam Sacred Heart Hospital, Catholic University Seoul St. Mary's Hospital, and Catholic University St. Vincent's Hospital.
  • Animal Cell Technology Center (동물세포실증지원센터)majorStrategic or Co-development Partner · 13 July 2020COVID-19 vaccine production cooperation agreement. Center provides GMP manufacturing facility and expertise for clinical trial vaccine production. Located in Andong Bioindustry Complex with BSL-level facilities and 16,120m² GMP manufacturing building. Partnership is part of a three-site production network (Seongnam GMP + Jeonnam JBRC + Andong Animal Cell Center).
  • Samsung Medical Center (삼성서울병원)majorStrategic or Co-development PartnerInvestigator-initiated clinical trial of BVAC-C in combination with Durvalumab for recurrent cervical cancer, led by Professor Byung-Kee Kim. Trial approved August 2020 (25 patients). Phase 2 results presented at SGO 2025 and ASCO 2024. Samsung Medical Center serves as lead site for BVAC-C + checkpoint inhibitor combination studies.
  • Handok Co., Ltd. (한독)minorOthersCEO Kang Chang Yuil serves as Non-Executive Director at Handok Co., Ltd., a listed Korean pharmaceutical company, providing potential strategic connection to pharmaceutical distribution and commercialization networks.

Scale indicators8 records

Recent moves11 records

Expansion highlights6 records

Cellid competitors and assessment

Company assessment

Broad incumbents

  • BioNTech: mRNA-based cancer vaccine pipeline (BNT122/iNeST, BNT111, etc.) and infectious disease vaccines. Comparable to Cellid as a leading therapeutic cancer vaccine developer with multiple oncology programs targeting similar indications (HPV-driven cancers, melanoma, personalized neoantigens).
  • Novavax: Recombinant nanoparticle vaccine developer for infectious diseases (COVID-19, influenza, RSV) with Matrix-M adjuvant platform. Comparable to Cellid on the infectious disease vaccine side (AdCLD-CoV19 series) where both pursued COVID-19 vaccines and faced mRNA-driven competitive pressure.
  • Moderna: mRNA platform with extensive oncology vaccine pipeline (mRNA-4157/V940 individualized neoantigen therapy, mRNA-5671 KRAS, Merck partnership) plus infectious disease vaccines. Highly comparable therapeutic cancer vaccine approach to CeliVax and BVAC-Neo via individual neoantigen targeting.

Regional players

  • Celltrion: Korean biopharma leader with biosimilars, novel biologics, and CDMO services through Celltrion Pharm. Comparable to Cellid as a Korean biopharma with significant GMP manufacturing scale and CDMO operations, illustrating the scale gap and providing a benchmark for Korean biopharma CDMO economics.
  • Genexine: Korean KOSDAQ-listed biotech developing immunotherapies and DNA vaccines, including therapeutic cancer vaccine candidates (GX-188E for HPV-driven cervical cancer). Comparable to Cellid as a fellow Korean biotech operating in therapeutic cancer vaccines and HPV-driven indications, though with a DNA vaccine rather than APC approach.

Direct peers

  • CureVac: mRNA-based cancer vaccine developer (CV8102, CV9202, personalized neoantigen vaccines) and infectious disease vaccines. Comparable to Cellid as a smaller-cap cancer/infectious disease vaccine biotech with platform-anchored multiple indication expansion strategy.
  • Gritstone bio: Clinical-stage biotech developing personalized neoantigen cancer vaccines (similar to Cellid's BVAC-Neo). Both companies pursue individualized cancer immunotherapy using patient-specific tumor antigens, making Gritstone the most directly comparable peer on the personalized vaccine side of CeliVax.
  • VBI Vaccines: Vaccine biotech developing prophylactic and therapeutic vaccines including enveloped virus-like particle (eVLP) platforms for infectious disease and immunotherapeutic candidates. Comparable to Cellid as a small-cap multi-platform vaccine company pursuing both infectious disease and oncology indications.
  • Bavarian Nordic: Vaccine-focused biotech with both infectious disease (smallpox/mpox, COVID-19, RSV) and oncology immunotherapy vaccine programs. Comparable to Cellid for its dual focus on prophylactic vaccines plus therapeutic cancer vaccines (CV301, BN-CV301) and global commercial reach.

Emerging players

  • JW Therapeutics: Asia-Pacific cell therapy company developing CAR-T therapies (Carteyva/relmacabtagene autoleucel) with integrated GMP manufacturing. Comparable to Cellid on the cell/gene therapy manufacturing side given Cellid's GMP facility and CDMO ambitions for cell therapy and viral vector production.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cellid compliance and trust

Trust signal

Compliance5 records

Cellid financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellid leadership team

Management profile

Number of profiles

Profiles5 records

Cellid funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellid M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellid

What does Cellid do?

Cellid develops anti-cancer immunotherapy vaccines built on its proprietary CeliVax platform, which uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells combined with tumor antigen genes and alpha-galactosyl ceramide adjuvant to activate multiple anti-tumor immune pathways. The portfolio includes the BVAC pipeline (BVAC-C, BVAC-E6E7, BVAC-B, BVAC-P, BVAC-M, BVAC-Neo) targeting cervical, head and neck, gastric, prostate, melanoma, and personalized cancers, plus the AdCLD-CoV19 series of COVID-19 preventive vaccines. Cellid also operates GMP-certified manufacturing facilities offering CDMO services for cell therapy, gene therapy, and viral vector production to domestic and international biotech and pharmaceutical clients.

Is Cellid a public or private company?

Cellid is a public company. It is classified as public and is currently operating.

When was Cellid founded?

Cellid was founded in 2006. It employs 11 to 50 people.

Where is Cellid based?

Cellid is headquartered in Seoul, South Korea, in the Asia region.

How does Cellid make money?

Four revenue lines are on record. Biopharmaceutical Licensing & Royalties are the primary driver. The others are CDMO / CMO Services, COVID-19 Vaccine Product Sales and E-commerce (Gomeon brand).

Who are Cellid's main competitors?

Broad incumbents on record are BioNTech, Novavax and Moderna. Regional players are Celltrion and Genexine. Direct peers are CureVac, Gritstone bio, VBI Vaccines and Bavarian Nordic. JW Therapeutics is listed as an emerging player.

Does Cellid have an API?

No public API is recorded for Cellid.

What industry is Cellid in?

Cellid's product category is Cancer Immunotherapy Vaccines. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAAABAF, Dendritic Cell & Other APC-based Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals